Science & Technology
Development of a Drug Candidate for the Treatment of Agitation in Alzheimer's Disease
Department of Health and Human Services — National Institutes of Health
Opportunity #: 1R44AG090144-01A1
Award Ceiling
$496K
Award Floor
$496K
Close Date
Sep 19, 2026
188 days leftTotal Funding
$496K
Expected Awards
1
Posted Date
Sep 20, 2025
Cost Sharing Required
No
Grants.gov ID
sbir-1R44AG090144-01A1
Description
SBIR Phase Phase I award: "Development of a Drug Candidate for the Treatment of Agitation in Alzheimer's Disease" awarded to PsychoGenics Inc. in Paramus, New Jersey. Funded by Department of Health and Human Services (National Institutes of Health). Award amount: $495,699. The SBIR/STTR programs fund innovative research and development by small businesses, with Phase I for feasibility studies and Phase II for full R&D.
Eligible Applicants
Small businesses
Apply on Grants.gov
Always verify details and apply through the official Grants.gov portal. Information here may not reflect the latest changes.
View on Grants.govDisclaimer: This information is sourced from Grants.gov and may not reflect the most current details. Always verify eligibility requirements, deadlines, and application procedures on the official program website before applying.